Joint Operations Ltd’s Post

The comprehensive Positive Quality Intervention (PQI) on the utilization of nirogacestat in the management of adults with progressing desmoid tumors (or fibromatosis/aggressive fibromatosis) provides insight into the initiation and management protocols for adult patients. Highlighting the latest guidelines, this precise and concise clinical guidance resource outlines the dosage forms now available, including: 50 mg (180-count bottle) 100 mg (14-count blister pack) 150 mg (14-count blister pack) tablets Stay informed and elevate your clinical practices with this invaluable resource tailored for optimal patient care. https://bit.ly/3ulJvXa

This new State-of-the-Art provides a thorough examination of antithrombotic therapy following transcatheter interventions such as TAVI, PFO closure, and TMVI. It highlights the delicate balance required in antithrombotic strategies to prevent device-related thrombosis while managing bleeding risks, particularly in high-risk patients. Important highlights include: 📌 The evolving guidelines for antithrombotic therapy post-TAVI. 📌 Evidence gaps and ongoing trials aimed at refining these strategies. 📌 The importance of personalized therapy based on patient and procedure-specific factors. https://ow.ly/pnrY50T1QqC

Join us this THURSDAY for Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

🤔 Are opioids the best choice for treating acute spinal pain? 🤔 Recent insights from the OPAL trial (Jones et al., 2023) suggest that opioids may not provide the pain relief many expect for acute low back and neck pain. With no significant improvement over placebo and a notable risk for misuse, it’s time to rethink our approach. Non-pharmacological and non-opioid treatments are increasingly recommended for managing acute spinal pain. 📊 Stay tuned! Tomorrow, we’ll share an infographic that breaks down the OPAL trial’s findings and explores the clinical implications for your practice. 📖 Reference: Jones, C. M. P., Day, R. O., Koes, B. W., Latimer, J., Maher, C. G., McLachlan, A. J., et al. (2023). The Lancet. #HealthcareEducation #AcutePainManagement #OpioidsInPain #AMPHealthcare #Clinicians #MedicalEducation

Unlock Mondays with an exciting publication! Are you curious about the effectiveness of anti-VEGF monotherapy compared to combination therapy with steroids for diabetic macular edema? Check out the publication 'Anti-VEGF Monotherapy vs Anti-VEGF and Steroid Combination Therapy for Diabetic Macular Edema: A Meta-analysis.' This meta-analysis evaluates treatment outcomes, providing insights into the benefits and drawbacks of each approach. With diabetic macular edema being a leading cause of vision loss, understanding the most effective treatment strategies is crucial for optimizing patient care. The findings may influence clinical decision-making and guide future research directions. What does this mean for your practice? Discover it: https://lnkd.in/d8pv5w9w #Ophthalmology #Publication #DiabeticMacularEdema #AntiVEGF #CombinationTherapy

Join us for our upcoming webinar, Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

Is Myocardial Infarction Overdiagnosed? Up to 20% Misdiagnoses The risk of overdiagnosing MI appears to be higher than underdiagnosing it. Some studies have estimated a 9% diagnostic error rate in patients clinically suspected of having an MI. In certain clinical trials, these diagnostic errors were found to be as high as 15%-20% after secondary analysis and strict application of MI definitions. A Universal Definition of Myocardial Infarction? This is what payers are using to clinically validate MI. Physicians must use their clinical judgment, applying the Universal Definition of MI, and describe, tell, and show the patient's clinical story with signs/symptoms of cardiac ischemia to correlate with other clinical tests to support the diagnosis of MI. Payers are focusing on NSTEMIs/Type II MI and throwing out the diagnosis left right and center. CDIS's role is to ensure proper documentation that supports the MI, providing feedback in the event of denials and promoting complete and accurate documentation in the first place. Remember, it is far better to educate physicians on documentation practices than queryrate. #CDI, #MI, #praoactive, #reactive, #doingright, #denialsavodiance, #overdiagnosisofMI, #misdiagnosis https://lnkd.in/dvnkHGFY

🔍 Dr. A. Sidney Barritt IV presented new, exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/eqRYzPkk #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024

Come and join us for an insightful discussion on a highly pertinent subject led by speaker Dr. Janet B. McGuill MD, MA, FACE, FACP. Below are the outlined goals for this engaging session: 1. Interpret guideline recommended criteria for prompt recognition and diagnosis of CKD in patients with T2D 2. Assess the latest clinical evidence for therapeutic agents for the management of CKD in patients with T2D that provide cardiorenal protective benefits 3. Choose strategies for selecting the right patient to minimize cardiovascular risks and CKD progression #CME#PALH

Do you ever wonder how those carefully defined protocols in a clinical trial get translated into actual clinical practice? In our recent webinar, "Expert Opinions on Navigating Frontline Therapy & Bispecifics in DLBCL", a community oncologist asked if they should follow the protocol from the POLARIX trial and administer 2 cycles of rituximab maintenance after R-CHP-Pola, or if they should skip it like they do with R-CHOP. Dr. Mayur Narkhede, our expert panelist, provided his perspective on how real clinical practice for these patients differs from the protocol in the clinical trial. https://lnkd.in/gAixxMQ7